Area of Interest: Research and Development
What we are looking for:
|
As a worldwide leader in pain, we are well placed to create innovative solutions for patients with various pain diseases. We are looking for partnerships for Rx products as well as medical devices. In addition to pain, we are expanding our portfolio with drugs in development (or already approved) in pain-related indications like osteoporosis, inflammation and others, as well as small / orphan indications where there is a high unmet medical need, e.g. diseases such as Duchenne, Parkinson or fibrosis. To achieve this, we continue to invest in R&D with more than 20 % of revenues. For more information on R&D at Grünenthal, please visit the R&D section of our website.
|
|
Read our recent press releases on Grünenthal partnering projects in R & D
-
Grünenthal receives Breakthrough Therapy Designation from U.S. FDA for neridronic acid for the treatment of complex regional pain syndrome (CRPS), a debilitating orphan disease with high medical need
-
Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease
-
Grünenthal’s cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain
-
A research consortium under the direction of Grünenthal will receive a grant of €1.5 million from the European Fund for Regional Development and the Federal State of North Rhein-Westphalia
-
Grünenthal and AstraZeneca enter into license agreement for lesinurad in Europe and Latin America
-
Grünenthal announces exclusive license agreement for commercialization of innovative surgical glue in the EU and Latin America
-
Drug Discovery Collaboration between Grünenthal and Axxam
-
Patheon selected by Grünenthal to develop drugs using Intac® abuse deterrent formulations technology
-
Grünenthal sets a strong sign of commitment for the future of their Research & Development
-
Grünenthal and Akashi Therapeutics Inc. announce joint drug development program for HT-100 in the treatment of patients with Duchenne Muscular Dystrophy (DMD)
-
Grünenthal's Innovative Medicines Unit (IMU) opens its first Innovation Hub to further strengthen the company’s networked Research and Development approach
-
Grünenthal GmbH exclusively licenses U.S. and Canadian rights of its innovative analgesic Cebranopadol to Depomed, Inc., confirming their strategic partnership
-
Grünenthal GmbH, Nordic Bioscience A/S and Argenta Discovery 2009 Ltd. enter into research collaboration in fibrosis
-
Grünenthal’s Zalviso® 15 micrograms sublingual tablets receives positive CHMP opinion in the EU for treatment of acute moderate to severe post-operative pain in adult patients
-
Grünenthal, Boston Children’s Hospital and Proteus S.A. announce a partnership and development program for neosaxitoxin
-
Grünenthal Announces Termination of License Agreement with Actavis for the Development of Cebranopadol as of October 1, 2014
-
AcelRx and Grünenthal Announce Submission of European Marketing Authorization Application for ZALVISO™
-
Grünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO®
-
Grünenthal takes over a product portfolio of BIOGEN® LABORATORIOS
-
Grünenthal and Amura Therapeutics LTD sign Agreement for Research Collaboration in Pain and Inflammation
-
The Grünenthal Group Enters into Exclusive Agreement with Horizon Pharma for Commercialization of DUEXIS® in Latin America
-
FDA approval of reformulated scheduled analgesic product using Grünenthal's INTAC™ technology
